US Patent

US10117936 — Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Formulation · Assigned to Tonix Pharma Holdings Ltd · Expires 2034-03-14 · 8y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions and methods of manufacturing eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride with mannitol.

USPTO Abstract

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Drugs covered by this patent

cyclobenzaprine-hydrochloride (CYCLOBENZAPRINE HYDROCHLORIDE)

Patent Metadata

Patent number: US10117936
Jurisdiction: US
Classification: Formulation
Expires: 2034-03-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Tonix Pharma Holdings Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.